Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression

Oncotarget
Fat-Moon SukYu-Chih Liang

Abstract

Bortezomib (Velcal) was the first proteasome inhibitor to be approved by the US Food and Drug Administration to treat patients with relapsed/refractory multiple myelomas. Previous studies have demonstrated that bortezomib inhibits tumor cell proliferation and induces apoptosis by blocking the nuclear factor (NF)-κB pathway. However, the exact mechanism by which bortezomib induces cancer cell apoptosis is still not well understood. In this study, we found that bortezomib significantly inhibited cell proliferation in both human Burkitt's lymphoma CA46 and Daudi cells. Through proteomic analysis, we found that bortezomib treatment changed the expression of various proteins in distinct functional categories including unfolding protein response (UPS), RNA processing, protein targeting and biosynthesis, apoptosis, and signal transduction. Among the proteins with altered expression, hnRNP K, hnRNP H, Hsp90α, Grp78, and Hsp7C were common to both Daudi and CA46 cells. Interestingly, bortezomib treatment downregulated the expression of high-molecular-weight (HMw) hnRNP K and c-Myc but upregulated the expression of low-molecular-weight (LMw) hnRNP K. Moreover, cell proliferation was significantly correlated with high expression of HMw hnR...Continue Reading

References

Jan 1, 1994·Radiographics : a Review Publication of the Radiological Society of North America, Inc·J E Hamrick-TurnerR V Iyer
May 1, 1996·Molecular and Cellular Biology·E F MichelottiD Levens
May 12, 2000·Gene·E T YehT Kamitani
Nov 17, 2001·American Journal of Clinical Pathology·P J Elliott, J S Ross
Jun 8, 2002·Molecular and Cellular Biology·Antje Ostareck-LedererMatthias W Hentze
Oct 17, 2003·British Journal of Cancer·J Ostrowski, K Bomsztyk
Apr 15, 2004·Molecular and Cellular Biology·Maria T Vassileva, Michael J Matunis
May 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Tianwei LiP Boon Chock
Mar 1, 2005·Oncogene·Yin-Yuan MoWilliam T Beck
Apr 14, 2005·Molecular Cancer Therapeutics·Dharminder ChauhanKenneth C Anderson
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Oct 28, 2005·Essays in Biochemistry·Yihong Ye
May 16, 2006·Nature Cell Biology·Jung Hwa KimSung Hee Baek
May 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·Atsushi InoueRenu Wadhwa
Feb 26, 2008·Cellular Signalling·Kavithalakshmi SataranatarajanDenis Feliers
May 13, 2008·FEBS Letters·Yibin ChenGengxi Hu
Sep 17, 2008·Biochemical Society Transactions·Denis TempéGuillaume Bossis
Nov 26, 2008·BMC Biochemistry·Dharminder ChauhanKenneth C Anderson
Sep 26, 2009·Clinical Lymphoma & Myeloma·Vaishalee P Kenkre, Wendy Stock
May 14, 2010·The Biochemical Journal·Kevin A Wilkinson, Jeremy M Henley
Mar 9, 2011·Experimental Biology and Medicine·Beat M RiedererIrène M Riederer
Jun 2, 2011·Journal of Clinical and Experimental Hematopathology : JCEH·Naoto Tomita
Jan 21, 2012·British Journal of Haematology·Ian Magrath
Feb 16, 2012·Lancet·Elizabeth M MolyneuxSimon Bailey
Jan 25, 2014·Trends in Cell Biology·Gary Kleiger, Thibault Mayor
Feb 6, 2014·International Journal of Hematology·Naohiro SekiguchiNaoki Takezako
Mar 15, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wei-Hwa LeeYu-Chih Liang

❮ Previous
Next ❯

Citations

Nov 25, 2017·British Journal of Haematology·Markus SchickUlrich Keller
May 13, 2018·International Journal of Molecular Sciences·Fat-Moon SukYu-Chih Liang
Jun 17, 2020·Journal of Experimental & Clinical Cancer Research : CR·Antonietta Rosella FarinaAndrew Reay Mackay
May 30, 2020·The Journal of International Medical Research·Er Chen, Renzhi Pei
Jul 1, 2020·Frontiers in Cell and Developmental Biology·Andrea CerasuoloMaria Lina Tornesello
Feb 23, 2019·International Journal of Molecular Sciences·Anne-Claire GodetAnne-Catherine Prats
Jul 29, 2018·Journal of Experimental & Clinical Cancer Research : CR·Go J Yoshida
Jan 3, 2021·Cellular and Molecular Life Sciences : CMLS·Subhashis NatuaSanjeev Shukla

❮ Previous
Next ❯

Methods Mentioned

BETA
sumoylation
electrophoresis
immunoprecipitation
transfection
Assay

Software Mentioned

PDQuest
ProteinLynx Global Server
SUMOplot Analysis
Raw2MSM
SPSS
SUMOplot
Mascot Daemon
MassLynx

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis